Outcomes in CF Patients Accessing Their Registry Health Records (CFView)
Primary Purpose
Cystic Fibrosis
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
CFView
CF educational videos
Sponsored by
About this trial
This is an interventional supportive care trial for Cystic Fibrosis
Eligibility Criteria
Inclusion Criteria:
- diagnosed with CF
- registered with their national CF patient registry
- FEV1pp ≥40
- aged 13-30 years
Exclusion Criteria:
- organ transplantation
- FEV1pp <40
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Active Comparator
Active Comparator
No Intervention
Arm Label
CF View
CF Educational videos
CF View and videos
Usual standard of care
Arm Description
Outcomes
Primary Outcome Measures
FEV1pp
forced expiratory volume in 1 second percentage predicted
Secondary Outcome Measures
Health literacy
Health Literacy Survey - HLS- EU - Q16 score
Health-related quality of life
CFQr score - (Cystic Fibrosis questionnaire revised)
BMI
kg/m^2
Pulmonary exacerbations
pulmonary exacerbation requiring IV antibiotics
Hospitalisations
hospitalisation for treatment of pulmonary exacerbation
Full Information
NCT ID
NCT03434886
First Posted
February 8, 2018
Last Updated
February 14, 2018
Sponsor
Cystic Fibrosis Registry of Ireland
1. Study Identification
Unique Protocol Identification Number
NCT03434886
Brief Title
Outcomes in CF Patients Accessing Their Registry Health Records
Acronym
CFView
Official Title
Evaluating Outcomes in European Cystic Fibrosis Patients With Access to Their Health Records: a Randomised Control Trial of a Registry Patient Portal
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
March 2016 (Actual)
Primary Completion Date
September 2017 (Actual)
Study Completion Date
September 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cystic Fibrosis Registry of Ireland
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A multifactorial, parallel group, randomised control study in cystic fibrosis (CF) patients aged 13-30 years over an 18 month period. Patients will be offered read-only access to their CF registry electronic health record (CF View), or educational videos on CF (videos), or videos and CF View, or usual standard of care. The study aims are to examine the effect of patient access to C View on a range of clinical outcomes, health service usage, health literacy and patient reported outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
282 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CF View
Arm Type
Experimental
Arm Title
CF Educational videos
Arm Type
Active Comparator
Arm Title
CF View and videos
Arm Type
Active Comparator
Arm Title
Usual standard of care
Arm Type
No Intervention
Intervention Type
Other
Intervention Name(s)
CFView
Intervention Description
Registry patient portal
Intervention Type
Other
Intervention Name(s)
CF educational videos
Intervention Description
CF educational videos
Primary Outcome Measure Information:
Title
FEV1pp
Description
forced expiratory volume in 1 second percentage predicted
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Health literacy
Description
Health Literacy Survey - HLS- EU - Q16 score
Time Frame
12 months
Title
Health-related quality of life
Description
CFQr score - (Cystic Fibrosis questionnaire revised)
Time Frame
12 months
Title
BMI
Description
kg/m^2
Time Frame
18 months
Title
Pulmonary exacerbations
Description
pulmonary exacerbation requiring IV antibiotics
Time Frame
18 months
Title
Hospitalisations
Description
hospitalisation for treatment of pulmonary exacerbation
Time Frame
18 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
diagnosed with CF
registered with their national CF patient registry
FEV1pp ≥40
aged 13-30 years
Exclusion Criteria:
organ transplantation
FEV1pp <40
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Outcomes in CF Patients Accessing Their Registry Health Records
We'll reach out to this number within 24 hrs